Labcorp Reports Full Year 2025 EPS of $10.46, Revenue Reaches $13.95 Billion
Labcorp Holdings Inc. (NYSE: LH) reported its fourth quarter and full year 2025 financial results on February 17, 2026, revealing annual earnings per share of $10.46 on revenue of $13.95 billion, according to the company's latest 8-K filing with the Securities and Exchange Commission.
Key Numbers
The diagnostic testing and drug development giant posted full year 2025 earnings per share of $10.46, reflecting the company's operational performance across its two main business segments. Annual revenue reached $13.95 billion for 2025, while net income totaled $880 million for the full year.
Quarterly performance data shows third quarter 2025 delivered earnings per share of $3.12 on revenue of $3.56 billion, with net income of $260 million. The second quarter 2025 saw stronger earnings per share of $5.36 on revenue of $6.87 billion, generating net income of $450 million during that period.
The earnings trajectory through 2025 demonstrates variability in quarterly performance, with Q2 showing particularly strong earnings per share at $5.36 compared to Q3's $3.12. This fluctuation reflects the seasonal nature of diagnostic testing volumes and the timing of drug development milestones across Labcorp's diverse portfolio of services.
Revenue distribution across the quarters shows Q2 2025 as the strongest revenue quarter at $6.87 billion, nearly double the Q3 figure of $3.56 billion. This significant quarterly variation highlights the impact of both testing volumes and project timing in the company's drug development services business.
What Management Said
While detailed management commentary was not included in the initial 8-K filing, the company's formal earnings press release referenced in Exhibit 99.1 would typically contain executive insights on performance drivers, market conditions, and strategic initiatives. The filing itself was signed by Kathryn W. Kyle, Executive Vice President, Chief Legal Officer and Corporate Secretary, confirming the accuracy and completeness of the reported financial data.
The timing of this earnings release, coming in mid-February 2026, follows standard quarterly reporting cycles for major healthcare companies. Labcorp's dual focus on diagnostic laboratory services and drug development services positions the company at the intersection of routine healthcare delivery and pharmaceutical innovation.
What to Watch
Several key metrics warrant attention in future quarters. The variation between Q2 and Q3 2025 performance suggests investors should monitor quarterly revenue stability and the factors driving period-to-period fluctuations. With Q2 revenue at $6.87 billion versus Q3's $3.56 billion, understanding the drivers of this volatility becomes crucial for forecasting future performance.
Earnings per share consistency will be another critical metric, particularly given the swing from $5.36 in Q2 to $3.12 in Q3. This 42% quarterly decline in EPS highlights the importance of tracking both operational efficiency and the impact of one-time items or seasonal factors on bottom-line results.
The company's ability to maintain margins while navigating the evolving healthcare landscape remains paramount. With full year net income of $880 million on revenue of $13.95 billion, Labcorp achieved a net margin of approximately 6.3%, a figure that bears watching as the company balances growth investments with operational efficiency.
Labcorp's position as a leading provider of diagnostic information services and drug development solutions places it at the center of two critical healthcare trends: the increasing importance of diagnostic testing in personalized medicine and the ongoing need for efficient drug development services. The company's financial performance will likely reflect broader industry dynamics, including reimbursement pressures in diagnostics and pharmaceutical R&D spending patterns.
Looking ahead, investors should focus on the company's ability to leverage its scale advantages in diagnostic testing while growing its higher-margin drug development services. The balance between these two segments will likely determine the company's earnings trajectory and its ability to deliver consistent returns to shareholders in an evolving healthcare marketplace.
*Source: Labcorp Holdings Inc. Form 8-K filed with the SEC on February 17, 2026*
*By StockCliff Research*